Gonadotropin-releasing hormone (GnRH) · Formerly FDA-approved (diagnostic; brand withdrawn)
A synthetic copy of the brain's gonadotropin-releasing hormone that tells the pituitary to release LH and FSH, historically used as a diagnostic agent.
✦ 2 min read · 2 sourcesWhat it is
Gonadorelin is synthetic gonadotropin-releasing hormone (GnRH). The FDA had approved it (brand Factrel) for evaluating hypothalamic-pituitary-gonadal axis function via the GnRH stimulation test; the brand was later withdrawn from the market for commercial, not safety, reasons. Current U.S. supply is largely through compounding pharmacies.
How it works
GnRH from the hypothalamus normally signals the pituitary in pulses. Delivered in a pulsatile pattern, gonadorelin stimulates the pituitary to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which drive testicular testosterone production and sperm formation. Paradoxically, continuous (non-pulsatile) exposure desensitizes the receptor and suppresses LH/FSH instead.
What the evidence shows
Gonadorelin's ability to provoke LH and FSH release is well established and underpins its validated diagnostic GnRH-stimulation test, and pulsatile GnRH has a documented role in inducing ovulation in hypothalamic amenorrhea. However, robust modern controlled-trial evidence for its increasingly common off-label use to maintain testosterone or fertility in men on hormone therapy is limited. Its very short half-life (roughly 2–10 minutes) makes consistent pulsatile dosing practically challenging.
Quick check
Four questions, ~60 seconds, with a sourced result.
The honest take
A genuine, formerly FDA-approved hormone with established diagnostic use, but its popular use to maintain testosterone or fertility is off-label with limited modern trial support.
Status & safety
Gonadorelin is a prescription product; with the original brand withdrawn, legitimate access is typically via a clinician and compounding pharmacy, and male hormone-support use is off-label. As GnRH, it falls under prohibited gonadotropin-releasing hormone agents in sport under WADA category S2. Use should be clinician-supervised given dosing complexity and the off-label nature of most current applications.
Summaries of published, third-party research for educational purposes. Not medical advice; not a claim of efficacy or safety for any use.
New, plain-language summaries as the literature develops. Educational only — no products, nothing for sale.
Selective estrogen receptor modulator (SERM) · Investigational (compounded only)
An estrogen-blocking molecule that prompts the body to make more of its own testosterone, studied for men with secondary low testosterone who want to preserve fertility.
Read more →Melanocortin receptor agonist · FDA-approved (women only)
A brain-acting peptide that stimulates sexual desire and arousal through melanocortin receptors, FDA-approved for women but not for men.
Read more →Growth-hormone-releasing hormone (GHRH) analog · FDA-approved (HIV lipodystrophy)
A peptide that prompts the pituitary to release the body's own growth hormone, FDA-approved specifically to reduce excess abdominal fat in adults with HIV-associated lipodystrophy.
Read more →